According to IMS Health estimates, China is expected to become the world’s second-largest pharmaceutical market by 2018. That’s why we are boosting our investments in this country. In Nantong, an industrial city located 140 km north of Shanghai, we have now opened a new pharmaceutical manufacturing site that will produce medicines on China’s Essential Drugs List for the treatment of diabetes, cardiovascular disease and thyroid disorders.
Additionally, we will start in 2017 with the construction of a Life Science Center also located in Nantong in order to offer products and services for the Chinese pharmaceutical and biopharmaceutical industries.
Our company invests around € 170 million in the construction of the pharmaceutical manufacturing site. The investment in the Life Science Center is estimated at around € 80 million.